What is clinically relevant? [Design Issues]

posted by bebac_fan – US, 2018-04-06 22:53 (2600 d 06:04 ago) – Posting: # 18648
Views: 6,569

Dear Helmut:

I believe the spaghetti plots you posted are actually indicative of a infusion of unbound drug.

Release of the encapsulated form follows first order kinetics and is Sequential - kind of like metabolic clearance from parent --> metabolite.

Luckily, you also posted the parent/metabolite curve for doxorubinol. Because of similarity in process, if no free drug is infused, bound and unbound PK should follow the same general shape we see in parent + metabolite.

The fact that total + free dox concentrations are colinear is pretty strong evidence for co-infusion of bound + unbound. Further, the fact that there isn't a lag time in unbound, as well as a nonlinear shape, is evidence, too.

Thanks,
BF

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,683 registered users;
92 visitors (0 registered, 92 guests [including 10 identified bots]).
Forum time: 04:57 CEST (Europe/Vienna)

There are two possible outcomes: if the result confirms the
hypothesis, then you’ve made a measurement. If the result is
contrary to the hypothesis, then you’ve made a discovery.    Enrico Fermi

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5